methyl (3R,4S)-4-(4-chlorophenyl)piperidine-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: methyl (3R,4S)-4-(4-chlorophenyl)piperidine-3-carboxylate
• 化学式: C₁₃H₁₆ClNO₂
• 分子量: 253.729
• InChiKey: DXRLHHQCJXYHPB-NEPJUHHUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl (3R,4S)-4-(4-chlorophenyl)piperidine-3-carboxylate 在 锂硼氢 、 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 56.66h， 生成 tert-butyl trans-4-(4-chlorophenyl)-3-((4-(N-(2,4-dimethoxybenzyl)-N-isobutylsulfamoyl)-2,5-difluorophenoxy)methyl)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
  [FR] COMPOSÉS DE BENZÈNESULFONAMIDE ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES

  摘要：

  这项发明涉及苯磺酰胺化合物，作为其立体异构体、对映异构体、互变异构体或它们的混合物；或者它们的药用可接受盐、溶剂合物或前药，用于治疗钠通道介导的疾病或症状，如疼痛。

  公开号：

  WO2013064983A1
• 作为产物：
  描述：

  (3R,4S)-4-(4-氯苯基)-1-甲基哌啶-3-羧酸甲酯 在 1-氯乙基氯甲酸酯 、 甲醇 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 52.5h， 生成 methyl (3R,4S)-4-(4-chlorophenyl)piperidine-3-carboxylate
  参考文献：
  名称：

  [EN] BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
  [FR] COMPOSÉS DE BENZÈNESULFONAMIDE ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES

  摘要：

  这项发明涉及苯磺酰胺化合物，作为其立体异构体、对映异构体、互变异构体或它们的混合物；或者它们的药用可接受盐、溶剂合物或前药，用于治疗钠通道介导的疾病或症状，如疼痛。

  公开号：

  WO2013064983A1

文献信息

• BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
  申请人：XENON PHARMACEUTICALS INC.

  公开号：US20140296245A1

  公开（公告）日：2014-10-02

  This invention is directed to benzensulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of sodium channel-mediated diseases or conditions, such as pain.

  本发明涉及苯磺酰胺化合物，包括其立体异构体、对映异构体、互变异构体或其混合物；或其药学上可接受的盐、溶剂化合物或前药，用于治疗钠通道介导的疾病或病况，例如疼痛。
• US9630929B2
  申请人：——

  公开号：US9630929B2

  公开（公告）日：2017-04-25
• [EN] BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS DE BENZÈNESULFONAMIDE ET LEUR UTILISATION EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：XENON PHARMACEUTICALS INC

  公开号：WO2013064983A1

  公开（公告）日：2013-05-10

  This invention is directed to benzensulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of sodium channel-mediated diseases or conditions, such as pain.

  这项发明涉及苯磺酰胺化合物，作为其立体异构体、对映异构体、互变异构体或它们的混合物；或者它们的药用可接受盐、溶剂合物或前药，用于治疗钠通道介导的疾病或症状，如疼痛。
• SAR Studies of Piperidine-Based Analogues of Cocaine. 4. Effect of N-Modification and Ester Replacement
  作者：Pavel A. Petukhov、Jianrong Zhang、Alan P. Kozikowski、Cheng Z. Wang、Yan Ping Ye、Kenneth M. Johnson、Srihari R. Tella

  DOI：10.1021/jm0200153

  日期：2002.7.1

  A series of novel N- and 3alpha-modified piperidine-based analogues of cocaine were synthesized and tested for their ability to inhibit reuptake of DA, 5-HT, and NE by the DA, 5-HT, and NE transporters. N-Demethylation of trans-(+)-3alpha-piperidine-based ligands leads to improved activity at the SEAT and NET and modest changes at the DAT. Replacement of the N-methyl group in trans-(+)-ester 1a with phenylalkyl groups leads to a modest 2.3-fold improvement in activity at the SERT (K-i less than or equal to 3.27 muM), insignificant changes at the NET, and a 3.5-fold loss in activity at the DAT (K-i greater than or equal to 810 nM); however, such replacement in cis-(-)-ester 4, the more potent isomer of la, leads, in general, to a significant decrease in activity at all monoamine transporters (K-i > 1 muM). Other N-modified ligands, including the ligands with polar groups incorporated in the N-alkyl substituent (3e-g) and ligands lacking the basic nitrogen (3i and 6d), show decreased activity at all monoamine transporters, though ligands 3e-g are similar in potency at the NET to la. N-Norester 2a, a possible metabolite of the lead compound la, and alcohol 1c, a compound with a 3alpha-substituent that is more stable to metabolism than la, were selected for further behavioral tests in animals. Alcohol le and ester 2a are similar in potency at the DAT to cocaine, ester 1a, and oxadiazole 1b, and both fully substitute for cocaine and have potency similar to that of cocaine in drug discrimination tests. Like cocaine, 1c increased locomotor activity (LMA) monotonically with time, whereas 2a produces biphasic effects consisting of initial locomotor depression followed by delayed locomotor stimulation. An interesting difference between cocaine, ester 1a, alcohol 1c, and N-norester 2a is that 1c and 2a are significantly longer acting in LMA tests. Although this result was anticipated for alcohol 1c, it is rather surprising for 2a which has an ester function susceptible to hydrolysis, a pathway of in vivo deactivation of cocaine and its ester analogues. The present results may have important implications for our understanding of the pharmacological mechanisms underlying the behavioral actions of cocaine and of the structural features needed for the design of the new leads in the discovery of a cocaine abuse medication.